Based out of St. Joseph's Healthcare in Hamilton, Ontario, Canada, the institute is a clinical facility with strong research directions.

The institute has maintained this designation, and as of 2006, it services the Hamilton Niagara Haldimand Brant Local Health Integration Network, a community of 1.4 million people.

Accordingly, a number of asthma and COPD initiatives were launched, including the development of standardized techniques for symptom assessment, airflow limitation and bronchial hyperresponsiveness.

[2] From 2004-2005, the institute was relocated to four floors of the brand new Juravinski Innovation Tower, where more modern research laboratories and expanded clinical facilities were available.

[1] In early March 2009, Firestone researchers demonstrated that an experimental drug, mepolizumab can help reduce eosinophil production in sufferers of severe asthma.